Literature DB >> 22784805

Synthesis of selective agonists for the α7 nicotinic acetylcholine receptor with in situ click-chemistry on acetylcholine-binding protein templates.

John G Yamauchi1, Kimberly Gomez, Neil Grimster, Mikael Dufouil, Akos Nemecz, Joseph R Fotsing, Kwok-Yiu Ho, Todd T Talley, K Barry Sharpless, Valery V Fokin, Palmer Taylor.   

Abstract

The acetylcholine-binding proteins (AChBPs), which serve as structural surrogates for the extracellular domain of nicotinic acetylcholine receptors (nAChRs), were used as reaction templates for in situ click-chemistry reactions to generate a congeneric series of triazoles from azide and alkyne building blocks. The catalysis of in situ azide-alkyne cycloaddition reactions at a dynamic subunit interface facilitated the synthesis of potentially selective compounds for nAChRs. We investigated compound sets generated in situ with soluble AChBP templates through pharmacological characterization with α7 and α4β2 nAChRs and 5-hydroxytryptamine type 3A receptors. Analysis of activity differences between the triazole 1,5-syn- and 1,4-anti-isomers showed a preference for the 1,4-anti-triazole regioisomers among nAChRs. To improve nAChR subtype selectivity, the highest-potency building block for α7 nAChRs, i.e., 3α-azido-N-methylammonium tropane, was used for additional in situ reactions with a mutated Aplysia californica AChBP that was made to resemble the ligand-binding domain of the α7 nAChR. Fourteen of 50 possible triazole products were identified, and their corresponding tertiary analogs were synthesized. Pharmacological assays revealed that the mutated binding protein template provided enhanced selectivity of ligands through in situ reactions. Discrete trends in pharmacological profiles were evident, with most compounds emerging as α7 nAChR agonists and α4β2 nAChR antagonists. Triazoles bearing quaternary tropanes and aromatic groups were most potent for α7 nAChRs. Pharmacological characterization of the in situ reaction products established that click-chemistry synthesis with surrogate receptor templates offered novel extensions of fragment-based drug design that were applicable to multisubunit ion channels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22784805      PMCID: PMC3463225          DOI: 10.1124/mol.112.080291

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

1.  A glia-derived acetylcholine-binding protein that modulates synaptic transmission.

Authors:  A B Smit; N I Syed; D Schaap; J van Minnen; J Klumperman; K S Kits; H Lodder; R C van der Schors; R van Elk; B Sorgedrager; K Brejc; T K Sixma; W P Geraerts
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Inhibitors of HIV-1 protease by using in situ click chemistry.

Authors:  Matthew Whiting; John Muldoon; Ying-Chuan Lin; Steven M Silverman; William Lindstrom; Arthur J Olson; Hartmuth C Kolb; M G Finn; K Barry Sharpless; John H Elder; Valery V Fokin
Journal:  Angew Chem Int Ed Engl       Date:  2006-02-20       Impact factor: 15.336

Review 3.  Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine.

Authors:  Justin W Kenney; Thomas J Gould
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

4.  Structural determinants in phycotoxins and AChBP conferring high affinity binding and nicotinic AChR antagonism.

Authors:  Yves Bourne; Zoran Radic; Rómulo Aráoz; Todd T Talley; Evelyne Benoit; Denis Servent; Palmer Taylor; Jordi Molgó; Pascale Marchot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-11       Impact factor: 11.205

5.  Spectroscopic analysis of benzylidene anabaseine complexes with acetylcholine binding proteins as models for ligand-nicotinic receptor interactions.

Authors:  Todd T Talley; Samar Yalda; Kwok-Yiu Ho; Yitzhak Tor; Ferene S Soti; William R Kem; Palmer Taylor
Journal:  Biochemistry       Date:  2006-07-25       Impact factor: 3.162

Review 6.  Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

Authors:  Marina R Picciotto; Michele Zoli
Journal:  Front Biosci       Date:  2008-01-01

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  A genetically encoded calcium indicator for chronic in vivo two-photon imaging.

Authors:  Marco Mank; Alexandre Ferrão Santos; Stephan Direnberger; Thomas D Mrsic-Flogel; Sonja B Hofer; Valentin Stein; Thomas Hendel; Dierk F Reiff; Christiaan Levelt; Alexander Borst; Tobias Bonhoeffer; Mark Hübener; Oliver Griesbeck
Journal:  Nat Methods       Date:  2008-09       Impact factor: 28.547

Review 9.  Taking the time to study competitive antagonism.

Authors:  D J A Wyllie; P E Chen
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

10.  Nicotine binding to brain receptors requires a strong cation-pi interaction.

Authors:  Xinan Xiu; Nyssa L Puskar; Jai A P Shanata; Henry A Lester; Dennis A Dougherty
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  3 in total

1.  Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands.

Authors:  Jian Shen; Xi-Cheng Yang; Ming-Cheng Yu; Li Xiao; Xun-Jie Zhang; Hui-Jiao Sun; Hao Chen; Guan-Xin Pan; Yu-Rong Yan; Si-Chen Wang; Wei Li; Lu Zhou; Qiong Xie; Lin-Qian Yu; Yong-Hui Wang; Li-Ming Shao
Journal:  Acta Pharmacol Sin       Date:  2016-12-05       Impact factor: 6.150

2.  The binding orientation of epibatidine at α7 nACh receptors.

Authors:  Andrew J Thompson; Simon Metzger; Martin Lochner; Marc-David Ruepp
Journal:  Neuropharmacology       Date:  2017-01-12       Impact factor: 5.250

Review 3.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.